The AMDCC is an interdisciplinary consortium designed to develop new animal models that closely mimic the human
complications of diabetes for the purpose of studying disease pathogenesis, prevention and treatment. The consortium
consists of thirteen "pathobiology sites" that study complications such as diabetic nephropathy, uropathy,
neuropathy, cardiomyopathy and vascular disease.
Additional goals of the AMDCC are to define criteria to validate each diabetic complications for its similarity to
the human disease, test the role of candidate genes that emerge from human genetic studies, and facilitate the
exchange of models, tissues, reagents, and expertise between members of the consortium and the greater scientific
community.
To ensure that all models generated by the AMDCC are phenotyped for a full duration of diabetes and across all
relevant complications, the consortium has formed a close partnership with the
Jackson Laboratories and the NIDDK-funded
Mouse Metabolic Phenotyping Centers.